Pfizer's Challenge On Generic Marketing Exclusivity Waivers Rejected By FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Waiver and relinquishment of generic marketing exclusivity are permitted under the FD&C Act and promote marketplace competition, FDA says. Pfizer asserted that treating 180-day exclusivity as an "alienable" asset would encourage the filing of speculative ANDAs.